Abstract | OBJECTIVES: MATERIAL AND METHODS: Whole-exome sequencing was performed on 215 patients. Association analysis was performed on single- nucleotide variants (SNVs) and genes, and the validation was based on an independent genome-wide association study (GWAS). Based on the association and validation analyses the genetic variants were then selected for and used in weighted genetic risk score (wGRS) prediction models for leukopenia and neutropenia. RESULTS: Association analysis identified 50 and 111 SNVs, and 12 and 20 genes, for leukopenia and neutropenia, respectively. Of these SNVS 20 and 19 were partially validated for leukopenia and neutropenia, respectively. The genes SVIL ( p = 2.48E-06) and EFCAB2 (p = 4.63E-06) were significantly associated with leukopenia contain the partially validated SNVs rs3740003, rs10160013, rs1547169, rs10927386 and rs10927387. The wGRS prediction models showed significantly different risk scores for high and low toxicity patients. CONCLUSION:
|
Authors | Anna Svedberg, Niclas Björn, Benjamín Sigurgeirsson, Sailendra Pradhananga, Eva Brandén, Hirsh Koyi, Rolf Lewensohn, Luigi De Petris, María Apellániz-Ruiz, Cristina Rodríguez-Antona, Joakim Lundeberg, Henrik Gréen |
Journal | Lung cancer (Amsterdam, Netherlands)
(Lung Cancer)
Vol. 147
Pg. 106-114
(09 2020)
ISSN: 1872-8332 [Electronic] Ireland |
PMID | 32683206
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Deoxycytidine
- Carboplatin
- Gemcitabine
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Carboplatin
(adverse effects)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, genetics)
- Deoxycytidine
(analogs & derivatives)
- Genome-Wide Association Study
- Humans
- Leukopenia
(chemically induced, genetics)
- Lung Neoplasms
(drug therapy, genetics)
- Neutropenia
(chemically induced, genetics)
- Exome Sequencing
- Gemcitabine
|